文献速递产科母胎医学

黄体酮预防早期妊娠出血流产的成本效果分析:基于PRISM试验

The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial.
PubMed 文献 · BJOG · 2020-01-30

黄体酮组每例平均费用比安慰剂组多76英镑(95%CI -559至711),每增加一例≥34周活产的成本为3305英镑。至少一次既往流产亚组中黄体酮效果差异0.055(95%CI 0.014-0.096)且节省费用322英镑(95%CI -1318至673)。

要点

  • 黄体酮组每增加一例≥34周活产的成本为3305英镑。
  • 至少一次既往流产者用黄体酮更有效且节省费用322英镑。
  • 总体效果差异小,但亚组分析更有利,尤其有流产史者。

核心结论

  • 黄体酮可能具有成本效果,尤其对于有既往流产史的女性。

主要发现

  • 黄体酮组每例平均费用比安慰剂组多76英镑(95%CI -559至711)。
  • 黄体酮相比安慰剂每增加一例≥34周活产的成本为3305英镑。
  • 至少一次既往流产亚组中,黄体酮效果差异0.055(95%CI 0.014-0.096)且节省费用322英镑(95%CI -1318至673)。

临床怎么用

  • 对于早期妊娠出血且有既往流产史的女性,黄体酮可能是具有成本效果的干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the cost-effectiveness of progesterone compared with placebo in preventing pregnancy loss in women with early pregnancy vaginal bleeding. DESIGN: Economic evaluation alongside a large multi-centre randomised placebo-controlled trial. SETTING: Forty-eight UK NHS early pregnancy units. POPULATION: Four thousand one hundred and fifty-three women aged 16-39 years with bleeding in early pregnancy and ultrasound evidence of an intrauterine sac. METHODS: An incremental cost-effectiveness analysis was performed from National Health Service (NHS) and NHS and Personal Social Services perspectives. Subgroup analyses were carried out on women with one or more and three or more previous miscarriages. MAIN OUTCOME MEASURES: Cost per additional live birth at ≥34 weeks of gestation. RESULTS: Progesterone intervention led to an effect difference of 0.022 (95% CI -0.004 to 0.050) in the trial. The mean cost per woman in the progesterone group was £76 (95% CI -£559 to £711) more than the mean cost in the placebo group. The incremental cost-effectiveness ratio for progesterone compared with placebo was £3305 per additional live birth. For women with at least one previous miscarriage, progesterone was more effective than placebo with an effect difference of 0.055 (95% CI 0.014-0.096) and this was associated with a cost saving of £322 (95% CI -£1318 to £673). CONCLUSIONS: The results suggest that progesterone is associated with a small positive impact and a small additional cost. Both subgroup analyses were more favourable, especially for women who had one or more previous miscarriages. Given available evidence, progesterone is likely to be a cost-effective intervention, particularly for women with previous miscarriage(s). TWEETABLE ABSTRACT: Progesterone treatment is likely to be cost-effective in women with early pregnancy bleeding and a history of miscarriage.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Okeke Ogwulu CB, Goranitis I, Devall AJ, et al. The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. BJOG. 2020. PMID: 32003141. doi:10.1111/1471-0528.16068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。